Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca.
Let's personalize your content